Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chemocentryx Inc (NQ: CCXI )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chemocentryx Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings
Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ: CCXI) following the Q4 results. Analyst Dae Gon Ha says he is "... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Trevi Therapeutics (NASDAQ:TRVI) shares rose 46.6% to $1.28 during Wednesday's regular session. As of 12:30 EST, Trevi Therapeutics's stock is trading at a... 
Via Benzinga
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported... 
Via Benzinga
Why ChemoCentryx Shares Are Falling
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading lower by... 
Via Benzinga
Recap: ChemoCentryx Q4 Earnings
ChemoCentryx (NASDAQ:CCXI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers IsoPlexis (NASDAQ:ISO) shares moved upwards by 22.8% to $5.5 during Wednesday's pre-market session. The company's market cap stands at $214.2 million. The... 
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, trader! It's time to start off another day of trading with the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Earnings Preview: ChemoCentryx
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Why ChemoCentryx Shares Are Rising
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher a... 
Via Benzinga
Expert Ratings For ChemoCentryx
Analysts have provided the following ratings for ChemoCentryx (NASDAQ:CCXI... 
Via Benzinga
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 46.4% to $0.4098 in pre-market trading after jumping around 48% on Tuesday. Guardion Health Sciences recently reported... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Is Now The Time To Buy Stock In ChemoCentryx, Ideanomics Or Snowflake?
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b... 
Via Benzinga
NASDAQ:CCXI Long Term Investor Alert: Investigation of Potential Wrongdoing at ChemoCentryx, Inc.
San Diego, CA -- (SBWIRE) -- 02/24/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of ChemoCentryx, Inc. 
Via SBWire
NASDAQ:CCXI Investor Notice: Investigation over Possible Securities Laws Violations by ChemoCentryx, Inc.
San Diego, CA -- (SBWIRE) -- 02/22/2022 -- ChemoCentryx, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
SHAREHOLDER ALERT: Robbins LLP Investigates ChemoCentryx, Inc. (CCXI) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis
The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of... 
Via Benzinga
ChemoCentryx, inc (CCXI) Q3 2021 Earnings Call Transcript
CCXI earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
Is It Too Late to Buy ChemoCentryx Stock?
The stock surged after obtaining FDA approval for avacopan. 
Via The Motley Fool
Exposures Product Safety
2 Super-Charged Growth Stocks to Buy Now
These two small drugmakers are poised for a long-winded growth spurt. 
Via The Motley Fool
45 Biggest Movers From Yesterday
Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on... 
Via Benzinga
BZ Chart Of The Day: ChemoCentryx
There’s an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCent... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021
Upgrades According to Vertical Research, the prior rating for C.H. Robinson Worldwide Inc (NASDAQ: 
Via Benzinga
Thinking About Buying Stock In Starbucks, Peloton Or ChemoCentryx?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS